Immunohistochemical Diagnosis of Primary Cardiac Leiomyosarcoma in a Latin American Patient

Blachman‐Braun, Ruben; Aboitiz-Rivera, Carlos Manuel; Aranda‐Fraustro, Alberto; Ransom-Rodríguez, Adrián; Baltazares-Lipp, Mario Enrique; Catrip-Torres, Jorge M.; Martínez-Reding, Jesús

doi:10.4081/rt.2017.6669

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Including the present case, only 30 cases with leiomyosarcoma of the pulmonary veins have been reported to date [ 2 , 7 , 8 , 9 , 10 , 11 , 12 ]. Owing to the scarcity of this disease, little is known about the optimal treatment modality of pulmonary vein leiomyosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Paclitaxel in a Patient with Inoperable Pulmonary Vein Leiomyosarcoma

et al. 2017

View full text Add to dashboard Cite

Pulmonary vein leiomyosarcoma is extremely rare and has a poor prognosis. Surgical resection with a wide margin seems to offer the only chance of cure. The role of adjuvant therapy is controversial, and the exact efficacy of chemotherapy has not been observed. In this report, we present an 18-year-old male patient with pulmonary vein leiomyosarcoma in whom the use of paclitaxel (PAX) proved to be effective. Because the tumor originated from the left superior pulmonary vein and diffused into the left atrial wall and the junction of the right superior pulmonary vein and left atrium, the en bloc excision of the tumor was impossible. The first-line chemotherapy, including ifosfamide, doxorubicin, and dacarbazine, in conjugation with radiation therapy could not demonstrate any effect on the tumor size. However, the following PAX-containing regimen provided complete regression of the tumor. After PAX-based high-dose chemotherapy with autologous peripheral blood stem cell transplantation, the patient showed complete remission for 2 years. Although he suffered metastatic recurrences and died 4 years after the onset of symptoms, our patient’s clinical course clearly reveals the efficacy of PAX.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Paclitaxel in a Patient with Inoperable Pulmonary Vein Leiomyosarcoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Necrotic and pleomorphic areas can often be detected [7,28]. As the cardiac LMSs are neoplasms arising from the smooth muscle cells and still keep their differentiation status, histology can point out positivity to desmin, α-smooth muscle actin, and myogenin, whereas they rarely show positive and focal stain for cytokeratins [7,30].…”

Section: Leiomyosarcomamentioning

confidence: 99%

Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology

Scicchitano¹,

Sergi

Cameli

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Primary malignant cardiac tumors are rare, with a prevalence of about 0.01% among all cancer histotypes. At least 60% of them are primary soft tissue sarcomas of the heart (pSTS-h) that represent almost 1% of all STSs. The cardiac site of origin is the best way to classify pSTS-h as it is directly linked to the surgical approach for cancer removal. Indeed, histological differentiation should integrate the classification to provide insights into prognosis and survival expectancy of the patients. The prognosis of pSTS-h is severe and mostly influenced by the primary localization of the tumor, the difficulty in achieving complete surgical and pharmacological eradication, and the aggressive biological features of malignant cells. This review aims to provide a detailed literature overview of the most relevant issues on primary soft tissue sarcoma of the heart and highlight potential diagnostic and therapeutic future perspectives.

show abstract

Right Ventricular Involvement of an Aggressive Malignant Peripheral Nerve Sheath Tumor

et al. 2022

View full text Add to dashboard Cite

We present a case of a 58-year-old woman who had a painful right thigh mass for a few months. A transthoracic echocardiogram revealed no evidence of an intracardiac mass. She had a whole-body positron emission tomography/computed tomography scan two months later that revealed masses in her right lower extremity and a mass in her right ventricle that had not been initially reported. She had been initially diagnosed with an undifferentiated pleomorphic sarcoma, but this diagnosis was changed to a malignant peripheral nerve sheath tumor with repeat pathology. She was subsequently hospitalized. An echocardiogram showed a mass covering 80% of her right ventricle (RV). Serial cardiac magnetic resonance imaging revealed a 9.4 x 5.6 cm RV mass with vascular and avascular portions and inflow and outflow tract obstruction. Computed tomography showed no other metastases. Due to a delay in diagnosis and a decline in left ventricular ejection fraction, the patient could not undergo palliative chemotherapy or radiotherapy.

show abstract

Immunohistochemical Diagnosis of Primary Cardiac Leiomyosarcoma in a Latin American Patient

Cited by 3 publications

References 18 publications

Efficacy of Paclitaxel in a Patient with Inoperable Pulmonary Vein Leiomyosarcoma

Efficacy of Paclitaxel in a Patient with Inoperable Pulmonary Vein Leiomyosarcoma

Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology

Right Ventricular Involvement of an Aggressive Malignant Peripheral Nerve Sheath Tumor

Contact Info

Product

Resources

About